Ocuphire Pharma announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants. Presbyopia, the gradual loss of ability to focus on near objects, typically becomes noticeable in the early to mid-40s. This progressive and ubiquitous condition leads to the widespread use of reading glasses or bifocals. Phentolamine Ophthalmic Solution 0.75% is being developed to provide a non-invasive, convenient alternative to traditional corrective measures.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- Ocuphire Pharma price target lowered to $18 from $20 at H.C. Wainwright
- Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
- Ocuphire Pharma reports Q2 EPS (30c) vs (24c) last year
- Ocuphire Pharma to Present at Two Investor Conferences in August
- OCUP Earnings this Week: How Will it Perform?